Bristol Myers’ Camzyos Achieves Phase 3 Success in Adolescent HCM Study
BMY•Bristol Myers Squibb announced its SCOUT-HCM Phase 3 trial met primary efficacy and safety endpoints for Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy, supporting a pediatric label expansion. The results bolster Camzyos’ growth trajectory following adult approvals and could drive incremental revenue from under-18 patients.
1. SCOUT-HCM Phase 3 Trial in Adolescents
Bristol Myers Squibb’s SCOUT-HCM study evaluated Camzyos (mavacamten) in patients aged 12–17 with symptomatic obstructive hypertrophic cardiomyopathy and met its primary efficacy and safety endpoints. These data pave the way for a pediatric label submission and expand Camzyos’ market beyond the adult oHCM population.
